Artificial Intelligence–Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2–Amplified Metastatic Colorectal Cancer: Exploratory Analysis of Phase II TRIUMPH Trial
JCO Precision Oncology · 2025
DOI: 10.1200/po-24-00385 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Mitsuho Imai und 19 weiteren Autor:innen. Beteiligte Einrichtung: Translational Research Support Office, National Cancer Center Hospital East, Chiba, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Tumor Microenvironment, Artificial Intelligence. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Human epidermal growth factor receptor 2 (HER2)–targeted therapies have shown promise in treating HER2 -amplified metastatic colorectal cancer (mCRC). Identifying optimal biomarkers for treatment decisions remains challenging. This study explores the potential of artificial intelligence (AI) in predicting treatment responses to trastuzumab plus pertuzumab (TP) in patients with HER2 -amplified mCRC from the phase II TRIUMPH trial. MATERIALS AND METHODS AI-powered HER2 quantification continuous score (QCS) and tumor microenvironment (TME) analysis were applied to the prescreening cohort (n = 143) and the TRIUMPH cohort (n = 30). AI analyzers determined the proportions of tumor cells (TCs) with HER2 staining intensity and the densities of various cells in TME, examining their associations with clinical outcomes of TP. RESULTS The AI-powered HER2 QCS for HER2 immunohistochemistry (IHC) achieved an accuracy of 86.7% against pathologist evaluations, with a 100% accuracy for HER2 IHC 3+ patients. Patients with ≥50% of TCs showing HER2 3+ staining intensity (AI-H3-high) exhibited significantly prolonged progression-free survival (PFS; median PFS, 4.4 v 1.4 months; hazard ratio [HR], 0.12 [95% CI, 0.04 to 0.38]) and overall survival (OS; median OS, 16.5 v 4.1 months; HR, 0.13 [95% CI, 0.05 to 0.38]) compared with the AI-H3-low (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Translational Research Support Office, National Cancer Center Hospital East, Chiba, Japan.
- Department of Genetic Medicine and Services, National Cancer Center Hospital East, Chiba, Japan.
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
- Lunit, Seoul, Republic of Korea.
- Department of Clinical Oncology, Hiroshima University Hospital, Hiroshima, Japan.
- Department of Surgery, NHO Osaka National Hospital, Osaka, Japan.
ORCID-Profile: Mitsuho Imai, Yoshiaki Nakamura, Sangwon Shin, Wataru Okamoto, Ken Kato, Yoshito Komatsu, Toshiki Masuishi, Kentaro Sawada, Riu Yamashita, Takao Fujisawa, Hideaki Bando, Chan-Young Ock, Satoshi Fujii, Takayuki Yoshino
Zitieren
APA
Imai, M., Nakamura, Y., Shin, S., Okamoto, W., Kato, T., Esaki, T., Kato, K., Komatsu, Y., Yuki, S., Masuishi, T., Nishina, T., Sawada, K., Sato, A., Kuwata, T., Yamashita, R., Fujisawa, T., Bando, H., Ock, C. Y., Fujii, S., & Yoshino, T. (2025). Artificial Intelligence–Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2–Amplified Metastatic Colorectal Cancer: Exploratory Analysis of Phase II TRIUMPH Trial. JCO Precision Oncology. https://doi.org/10.1200/po-24-00385
Vancouver
Imai M, Nakamura Y, Shin S, Okamoto W, Kato T, Esaki T, et al. Artificial Intelligence–Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2–Amplified Metastatic Colorectal Cancer: Exploratory Analysis of Phase II TRIUMPH Trial. JCO Precision Oncology. 2025. doi:10.1200/po-24-00385
BibTeX
@article{Imai2025,
author = {Imai, Mitsuho and Nakamura, Yoshiaki and Shin, Sangwon and Okamoto, Wataru and Kato, Takeshi and Esaki, Taito and Kato, Ken and Komatsu, Yoshito and Yuki, Satoshi and Masuishi, Toshiki and Nishina, Tomohiro and Sawada, Kentaro and Sato, Akihiro and Kuwata, Takeshi and Yamashita, Riu and Fujisawa, Takao and Bando, Hideaki and Ock, Chan-Young and Fujii, Satoshi and Yoshino, Takayuki},
title = {Artificial Intelligence–Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2–Amplified Metastatic Colorectal Cancer: Exploratory Analysis of Phase II TRIUMPH Trial},
journal = {JCO Precision Oncology},
year = {2025},
doi = {10.1200/po-24-00385}
}
EUVIMED